Abstract: An insulating glazing having at least two panels made of transparent or semi-transparent material is provided. At least one of these panels is a luminescent solar concentrator.

Abstract: Oligosaccharides are for use in the treatment of neurodegenerative diseases of the central nervous system, in particular Parkinson's disease, and to pharmaceutical compositions including one or more of the oligosaccharides.

Abstract: A detection system (101, 101b) of enteric diseases in animals includes a sensor device (102) having suction (103) for suctioning air from the animals' environment (11, 12). A sensor is (104) configured to determine information about the type and concentration of smelling molecules in the air and further configured to emit a signal representative of the information of smelling molecules. A transmission device (105) is configured to convey the signal representative of smelling molecules. A self-learning processing device (108) is configured to receive and process the signal representative of smelling molecules, and to detect a risk of enteric diseases in the animals associated with the information about the type and concentration of the smelling molecules. A signaling device (111) is configured to report to a user (10) the risk of enteric diseases in the animals, before the enteric diseases arise. A relative method detects enteric diseases in animals.

Abstract: Process for the plasma surface treatment under vacuum of a fabric, nonwoven fabric or paper material for obtaining materials to be used for the filtration and separation of two immiscible liquids.

Abstract: The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R1 is a saturated C8-C16 aliphatic chain having a =0 on C1, said chain being free from —OH substituents on C3, wherein R2 is a saturated C8-C16 aliphatic chain having a ?O on C1, said chain being free from —OH substituents on C3, wherein R3 is a saturated C8-C16 aliphatic chain having a ?O on C1, said chain being free from —OH substituents on C3; wherein R4 is a hydrogen atom (H) or a phosphate group (PO42?).

Abstract: Process for the plasma surface treatment under vacuum of a fabric, nonwoven fabric or paper material for obtaining materials to be used for the filtration and separation of two immiscible liquids.

Abstract: The present disclosure relates to delta-2-tubulin and its use as a biomarker for determining if a subject is at risk of developing peripheral neuropathy or if a subject has developed peripheral neuropathy. The present disclosure further relates to methods for the treatment of peripheral neuropathy in a subject and assays for identifying compounds that can be used to treat and/or prevent peripheral neuropathy.

Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

Abstract: The present invention relates to at least one modulator of PP2A or at least one modulator of PP2A-like phosphatase or at least one modulator of PP2A and PP2A-like phosphatase or a combination of said modulators for use in the treatment of a disease characterized by an alteration in the DNA damage response. The present invention also relates to a method to identify a subject to be treated with a PP2A modulator comprising detecting in the genome of said patient a mutation in PP2A.

Abstract: Disclosed are a colloidal coating dispersion containing electrochromic polymer particles, a method for manufacturing the colloidal coating dispersion, the use of the colloidal coating dispersion for depositing at least one electrochromic layer on a substrate, and an article including a layer deposited from the colloidal coating dispersion.

Abstract: It is described a method for realizing catalytically active electrochemical electrodes with maximized surface area. In the method, InGaN is deposited epitaxially in form of a thin layer on a Silicon substrate exposing a (111) crystal fac, thus forcing the InGaN electrode material to grow exposing a catalytically active surface. The substrate is then removed, the InGaN layer is made into fragments and these are transferred onto a conductive support with one-, two- or three-dimensional structure which can be a wire, a two-dimensional conductive foil which, possibly folded, or a three-dimensional conductive fabric, sponge or cage-like structure. It is thus possible to obtain an InGaN-based electrode with increased surface area and exposing surfaces with high catalytic activity.

Abstract: The present invention regards a solid master elastomeric composition (masterbatch, MB) comprising silicate fibres with needle-shaped morphology of nanometric size, characterised by high fibre content and uniformity, a process advantageous for the preparation thereof and its use in manufacturing tyres for vehicles. Advantageously the present elastomeric composition allows minimising the drawbacks associated with the handling of the powdery fibres in the manufacturing of compounds for tyres, without altering the final performances thereof.

Abstract: The present invention relates to novel heterocyclic derivatives having general formula (I) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like Alzheimer's or Parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (I) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications.

Abstract: The present invention relates to novel molecules suitable to the use in the separation/removal of carbon dioxide from gaseous mixtures as liquid-phase carbon dioxide absorbers and suitable to allow the subsequent release of the absorbed carbon dioxide in form of different ionic liquids, preferentially a glycine salt with choline hexanoate, ester between glycine and hexanoic alcohol (hexyl glycinate) and glycerol ester with glycine and hexanoic acid. The present invention also relates to a method and a plant for the capture of carbon dioxide from gaseous mixtures by using an absorber for carbon dioxide in liquid phase with a heating jacket.

Abstract: New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease.

Abstract: The inventors have made the surprising discovery that when ceramide production is upregulated in the infarct and at-risk areas upon reperfusion injury in the heart, such upregulation is effected through the de novo ceramide synthesis pathway. Upon treatment of cardiac tissues subject to reperfusion injury with a specific inhibitor of the novo ceramide synthesis pathway (myriocin), the inventors have determined that the inhibition of such pathway not only reduces the inflammation of the interested area, but most surprisingly reduces infarct size, ameliorates cardiac contractility and activates cell detoxification and survival programs. There is thus provided an inhibitor of de novo ceramide synthesis pathway, particularly myriocin, for the treatment of cardiac reperfusion injury.

Abstract: Chemical compounds are provided which act on GPR17 receptors and are useful in the treatment or amelioration of chronic and/or acute neurodegenerative diseases, such as multiple sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, and renal diseases.

Abstract: Disclosed are polymers with a complex branched structure (star- or tree-shaped) obtainable by polymerizing a bifunctional type AB monomer and/or type AA+BB monomers in the presence of: a) one or more polyamine and/or a polyacid and/or a polyalcohol and/or more generally a compound (such as POSS) having at least three functional groups such as amino, carboxylic acid or hydroxyl functions; b) one or more phosphorus containing molecules reacting with only one reactive group during the polymerization; c) optionally one or more organic acid and/or an amine and/or an alcohol having one or two functional groups.

Abstract: A blood treatment method is described that is adapted to at least partially eliminate the carbon dioxide content of the type comprising a step of drawing a blood flow. Advantageously according to the invention, the method further comprises the steps of: acidifying the blood flow with transformation of the related blood bicarbonate content into gaseous carbon dioxide; and eliminating the gaseous carbon dioxide content by means of a pressure gradient.

Abstract: The present invention relates to an extracorporeal circuit for CO2 removal from blood comprising a line for taking blood from the patient, a decarboxylation assembly and a line for returning the blood to the patient; said decarboxylation assembly comprising a first filtering unit, an oxygenator, an electrodialyzer adapted to generate an acid solution and a basic solution and means for the infusion of said acid solution upstream of said oxygenator, wherein said electrodialyzer comprises a first electrodialysis chamber and a second electrodialysis chamber, said first and second electrodialysis chambers being separated by an ionic membrane, and in that wherein said first chamber and said second chamber are respectively separated from the positive electrode, or anode, and from the negative electrode, or cathode, by means of a bipolar membrane.